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DIFFERENT GVHD CLINICAL PROFILE AMONG PATIENTS WHO RE-
CEIVED CORD BLOOD, COMPARED TO THOSE WHO RECEIVED MAR-
ROW OR PERIPHERAL BLOOD
Funke, V.A.M., Nunes, E.C., Medeiros, L., Setubal, D.C., Ruiz, J.,
Oliveira, M.M., Bittencourt, M.A., Bonfim, C., Neto, J.Z.,
Medeiros, C.R., Pasquini, R. Hospital de Clınicas - Federal University
of Parana, Curitiba, Parana, Brazil.
It is well known that transplants from cord blood stem cells have
lower incidence of graft-versus-host disease, which allows proce-
dures with more HLA disparities when compared to marrow. The
objective of this study, however is to determine if there is a different
clinical expression of GVHD beteween receptors of peripheral
blood/marrow versus cord blood.
Patients and Methods: From October 1979 to June 2007, 1530
patients were transplanted at the BMT center of the Federal Uni-
versity of Parana. We retrieved the database of our institution and
divided the patients into two categories. Group one: 1390 patients
who received bm or pb as stem cell source. Group 2: 140 patients
who received cord blood. Main differences between the two goups
are listed at the table below. Statystical Analysis: Kaplan Meier was
used for survival and Fisher test for comparison of categoric vari-
ables. Results: See table 1. Conclusions: 1. There was a lower in-
cidence of lung and oral involvement by chronic GVHD and
a higher incidence of gut involvement on patients who received
CB as compared to PB and Marrow. Furthermore, we did not see
any case of bronchiolitis obliterans in the CB group. 2. There was
less oral and more gut and liver involvement by acute GVHD in
the CB group. 3. Overall incidence of chronic GVHD was lower
for the cord blood group. There were a higher frequency of acute
GVHD grade II-IV among CB recipients, possibly because of the
increased frequency of HLA disparity.CB Marrow/PB: acute and chronic GVHD
Characteristics Group 1 (CB) Group2 (BM/PB) P valueN 140 1390
Age (M) years 6 20
SCT donor 0.0001
related 18 1235
unrelated 122 155HLA 0.0001
compatible 34 1296
1mismatch (A, B,DR) 47 89
other 59 5Male/Female 83/57 841/549
Sex mismatch (male
recipient/female
donor)40 (29%) 289 (21%)A-GVHD 51 (36%) 350 (45%) 0.0385
Grade III-IV 26/51 (51%) 113/350 (32%)
Skin 41 (80%) 297 (85%)
Liver 12 (24%) 141 (40%) 0.0212
Oral 2 (4%) 31 (8%)
Lung 0 4 (1%)
Gut 20 (15%) 89 (25%) 0.0440C-GVHD extensive 13/95 av (14%) 238/1115 av (21%)
severe 4/13 (30%) 95/238 (40%)
C-GVHD organ
Skin 7 (53%) 106 (45%)
Liver 10 (77%) 92 (39%) 0.0084
Oral 2 (15%) 108 (45%) 0.0434
Lung 1 *(7%) 36 (15%)
Gut 6 (46%) 48 (20%) 0.0376Survival (%) 68 (49%) 721 (52%)
Survival (M) days 196 (0–5231) 1028 (0–9078)*BOOP.366
ALLOSPECIFIC EFFECTOR MEMORY T CELLS HAVE DECREASED ABILITY
TO INDUCE ACUTE GVHD
Chen, B.J., Wu, J., DeOliveira, D., Chao, N.J. Duke University Med-
ical Center, Durham, NC.
Several different groups have independently demonstrated that
non-allospecific memory T cells do not induce GVHD. The data
related to the ability of allospecific memory T cells to induce
GVHD have not been conclusive. In order to study this question
more definitely, we have developed a novel GVHD model using
TEa TCR transgenic mice as donors. TEa CD41 TCR transgenic
mice (C57BL/6 background) express a TCR that recognizes the
peptide ASFEAQGLANIAVDKA in the context of I-Ab. This pep-
tide corresponds to positions 52–68 from the alpha-chain of I-E
class II molecules and is expressed in all APCs from H-2b/I-E1
strains such as CB6F1 mice. Titration experiment demonstrated
that as few as 1  105 TEa cells were able to induce lethal
GVHD in lethally irradiated CB6F1 recipients, making it an ideal
model to study the ability of allospecific memory T cells to induce
GVHD. Because sufficient numbers of allospecific memory pheno-
type T cells could not be obtained from the TEa mice or C57BL/6
CD45.1 mice containing TEa cells after priming, we chose the
Rag1-/- model. TEa cells were first parked in Rag1-/- mice and
then were immunized with irradiated CB6F1 cells. Eight weeks
later, TEa cells were harvested from the spleens and effector mem-
ory T cells were obtained after depletion of CD62L1 cells. Many
TEa cells that were parked in the Rag1-/- mice but were not immu-
nized with alloantigens also obtained the effector memory T cell
phenotype. These cells were termed as ‘‘unprimed TEM’’ while
those from primed animals were termed as ‘‘primed TEM’’. Both
primed and unprimed effector memory TEa cells were able to re-
spond to alloantigens in vitro. However, neither primed nor un-
primed effector memory TEa cells was able to induce lethal
GVHD in vivo and all animals in the effector memory T cell groups
survived more than 100 days post transplantation. In contrast, all
naive T cell recipients developed lethal GVHD and died within
35 days after transplantation. These data demonstrate that, similar
to non-allospecific memory T cells, allospecific effector memory
T cells also have decreased ability to induce GVHD when compared
with naive T cells. This is an excellent model for us to study the
unique immune response mediated by allospecific memory T cells
in GVHD.367
SURVIVAL AFTER EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR
TREATMENT OF GRAFT-VERSUS-HOST DISEASE (GVHD) IS PREDICTED
BY GVHD CLASSIFICATION AS PROPOSED BY NATIONAL INSTITUTE
OF HEALTH (NIH) CONSENSUS CRITERIA
Jagasia, M.1, Stricklin, G.2, Logue, M.1, Lucid, C.1, Fife, H.1,
Mitchell, J.1, Chen, H.3, Hunt, C.1, Kassim, A.1. 1Vanderbilt University
Medical Center, Nashville, TN; 2Vanderbilt University Medical Center,
Nashville, TN; 3Vanderbilt University Medical Center, Nashville, TN.
ECP is used in GVHD treatment with variable response. The
clinical phenotype of GVHD associated with ECP responsiveness
is not clear. Subtypes of GVHD proposed by NIH consensus crite-
ria affect survival after allogeneic stem cell transplant (SCT)
(BBMT 2007 Oct; 13(10):1207–15). We hypothesized that survival
after ECP will be determined by NIH subtypes of GVHD.
Methods: Review of patients undergoing ECP for GVHD treat-
ment was done. 55 patients (pts.) were identified and GVHD was
reclassified using NIH criteria. Pts. with acute GVHD (aGVHD)
were graded using Glucksberg criteria. Pts. with overlap or classic
chronic GVHD (cGVHD) were scored using NIH criteria. Overall
survival (OS) was measured from starting ECP. ECP indication was
steroid dependency or refractoriness. Results: Classic aGVHD
(26%), recurrent aGVHD (7%), overlap cGVHD (16%) and classic
cGVHD (51%) accounted for the subtypes. Pts. started ECP at
a median of 216 days after SCT (range, 41 to 2946). The median
number of GVHD recurrences prior to ECP start was 2 (range,
0–6). Pts. with classic cGVHD started ECP significantly later
(145 days vs. 53 days, P\ 0.001), continued it for a longer time
